Filgotinib Shaping Up To Be Success Story For Gilead and Galapagos
Executive Summary
Impressive Phase II data for Gilead and Galapagos’ filgotinib in psoriatic arthritis and progress into Phase III for ulcerative colitis suggest that the investigational JAK inhibitor could potentially become a market leader in the class for these and other inflammatory indications.
You may also be interested in...
Gilead Hopes Selectivity Will Ease Safety Labeling For Filgotinib
On pace to file selective JAK1 inhibitor filgotinib for US approval in RA by year’s end, Gilead says the drug’s safety profile may allow for a labeling advantage compared with other drugs in the class.
Galapagos Flies As Filgotinib Soars In FINCH Studies
More evidence of its strong safety profile suggests that the Belgian biotech's oral selective JAK1 inhibitor partnered with Gilead will be able to break into the crowded RA market.
Pharma Q2 Results Preview: Lilly, Biogen, GSK And Gilead
Key strategy updates are coming: GSK will unveil its new R&D approach, Biogen will update investors on its Alzheimer's plans, and investors are keen to find out whether or not Lilly will sell its animal health franchise. Investors will also be keeping an eye on how Gilead is faring with its move into oncology.